Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision 2: afatinib in advanced EGFR/HER2/HER3-mutated cancers
2016-003411-34Phase 2Completed
- Sponsor
- Belgian Society of Medical Oncology
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in cancer, sponsored by Belgian Society of Medical Oncology. Primary endpoint: Objective response rate. Started Dec 2016; status: completed.
02
Drugs
afatinib
03
Conditions
cancer
Beyond the preview
Go deeper on 2016-003411-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003411-34.